PharmaCyte Biotech Faces Delisting Notice
Ticker: PMCB · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1157075
| Field | Detail |
|---|---|
| Company | Pharmacyte Biotech, Inc. (PMCB) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
PharmaCyte Biotech got a delisting warning from the exchange.
AI Summary
PharmaCyte Biotech, Inc. filed an 8-K on December 5, 2025, reporting a notice of delisting or failure to meet continued listing requirements as of December 1, 2025. The company, previously known as NuVilex, Inc., is incorporated in Nevada and has its principal executive offices in Las Vegas.
Why It Matters
This filing indicates potential issues with PharmaCyte Biotech's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.
Key Players & Entities
- PharmaCyte Biotech, Inc. (company) — Registrant
- December 1, 2025 (date) — Date of earliest event reported
- December 5, 2025 (date) — Date of report
- NuVilex, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Las Vegas, Nevada (location) — Principal executive offices
FAQ
What is the specific reason for PharmaCyte Biotech's notice of delisting or failure to meet listing standards?
The provided text of the 8-K filing does not specify the exact reason for the delisting notice, only that it was issued as of December 1, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 5, 2025.
What was PharmaCyte Biotech's former company name?
PharmaCyte Biotech, Inc. was formerly known as NuVilex, Inc.
In which state is PharmaCyte Biotech, Inc. incorporated?
PharmaCyte Biotech, Inc. is incorporated in Nevada.
What is the address of PharmaCyte Biotech's principal executive offices?
The principal executive offices of PharmaCyte Biotech, Inc. are located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169.
Filing Stats: 838 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2025-12-05 17:00:25
Key Financial Figures
- $0.0001 — h registered Common Stock , Par Value $0.0001 Per Share PMCB The Nasdaq Stock Ma
- $1.00 — ties to maintain a minimum bid price of $1.00 per share, and, based on the closing bi
Filing Documents
- pharmacyte_8k.htm (8-K) — 28KB
- 0001683168-25-008947.txt ( ) — 190KB
- pmcb-20251201.xsd (EX-101.SCH) — 3KB
- pmcb-20251201_lab.xml (EX-101.LAB) — 33KB
- pmcb-20251201_pre.xml (EX-101.PRE) — 22KB
- pharmacyte_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHARMACYTE BIOTECH, INC. Date: December 5, 2025 By: /s/ Joshua N. Silverman Name: Joshua N. Silverman Title: Chief Executive Officer and President 3